These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 2217479

  • 1. Prognostic factor analysis from EORTC trials in advanced prostatic cancer. EORTC-GU Group.
    de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M.
    Prog Clin Biol Res; 1990; 357():69-72. PubMed ID: 2217479
    [No Abstract] [Full Text] [Related]

  • 2. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
    Németh A, Morvay J, Vécsei B.
    Orv Hetil; 1981 Apr 26; 122(17):1017-20. PubMed ID: 7022313
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [The prognostic significance of alkaline and acid phosphatase levels in the hormonal treatment of patients with prostatic carcinoma].
    Mulders PF, Debruyne FM.
    Ned Tijdschr Geneeskd; 1987 Aug 08; 131(32):1399-402. PubMed ID: 3658014
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic factors in patients with advanced stage prostate cancer.
    Emrich LJ, Priore RL, Murphy GP, Brady MF.
    Cancer Res; 1985 Oct 08; 45(10):5173-9. PubMed ID: 4027993
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.
    Murphy GP, Beckley S, Brady MF, Chu TM, deKernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, McKiel CF, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel JU, Schmidt JD, Scott WW, Slack NH, Soloway MS.
    Cancer; 1983 Apr 01; 51(7):1264-72. PubMed ID: 6337697
    [No Abstract] [Full Text] [Related]

  • 12. Time-dependent prognostic factors in advanced prostatic cancer.
    Suciu S, Sylvester RJ, Yamanaka H.
    Prog Clin Biol Res; 1990 Apr 01; 357():203-15. PubMed ID: 2217465
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ.
    Cancer Res; 2001 Mar 15; 61(6):2533-6. PubMed ID: 11289126
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S.
    Prog Clin Biol Res; 1989 Mar 15; 303():111-6. PubMed ID: 2528735
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.